（来源：深圳商报） "一边是创始人股权被司法拍卖，一边是紧急启动H股上市募资"，正陷入业绩滑坡困境的科创板上市公司悦康药业近期的一系列操作，让市场充满疑虑。 近日，悦康药业发布公告称，为进一步提高公司综合竞争力，提升公司国际品牌形象，同时更好地利用国际资本市场，多元化融资渠道，公司拟在境外发 行股份（H股）并在港交所主板上市。 根据公告，本次发行上市方案尚需提交公司股东大会审议，并需获得中国证监会、香港联交所等相关监管机构的备案、批准或核准。公司表示将在股东会 决议有效期内（即自公司股东会审议通过之日起24个月或同意延长的其他期限）选择适当的时机和发行窗口完成本次发行H股并上市。 资料显示，悦康药业集团股份有限公司成立于2001年，总部位于北京，是一家集新药研发、药品生产、流通销售及国际贸易于一体的医药集团企业。目前 已形成核酸药物靶点发现平台、多肽药物开发平台、缓控释制剂技术平台等九大核心研发平台，涵盖核酸药、多肽药、中药创新药以及高端化药等领域。 2020年12月24日，悦康药业在上海证券交易所科创板上市。然而，公司募投项目进展并不顺利。 2024年12月19日，悦康药业公告将研发中心建设、固体制剂生产线 ...

Core Viewpoint - The company is managing its temporarily idle raised funds in accordance with regulatory guidelines, ensuring effective use and risk prevention [1] Group 1 - The company has over 500 million in cash but prioritizes financial management over share repurchase, leading to over 40% of restricted funds and less than 200 million in actual available funds [1] - The board of directors is continuously monitoring the storage, management, and usage of raised funds to enhance their effectiveness and mitigate investment risks [1] - The company emphasizes compliance with the "Regulations on the Supervision of Raised Funds by Listed Companies" and other relevant self-regulatory guidelines [1]

Core Viewpoint - The article discusses the significant shift in the lithium battery industry, highlighting the overcapacity and the urgent need for Chinese lithium battery companies to seek international capital markets, particularly through IPOs in Hong Kong, to address financial pressures and enhance global competitiveness [5][7][14]. Group 1: Market Dynamics - The Hong Kong stock market is becoming a strategic supply station for lithium battery companies, with a nearly threefold increase in IPO fundraising in Q1 2025 compared to the previous year, marking the best start since 2021 [5]. - As of June 2025, there were 240 IPO applications on the Hong Kong Stock Exchange, nearly double the number from 2024, with lithium battery companies leading the charge [5][8]. - The global demand for power batteries is projected to reach 1000-1200 GWh by 2025, while the total planned capacity in the industry is as high as 4800 GWh, indicating a severe supply-demand imbalance [8]. Group 2: Financial Pressures - The lithium battery industry is experiencing structural pressures, including severe overcapacity, intense price competition, accelerated technological iteration, and tight cash flow, pushing companies to seek foreign capital [7][9]. - Many companies are facing deteriorating cash flow, with an average collection period of 103 days and a payment period of 255 days, leading to significant cash flow challenges [8]. - The average debt ratio for some companies exceeded 70% in the first half of 2025, indicating a growing liquidity crisis that necessitates new financing channels [9]. Group 3: Globalization Strategy - The urgent need for a globalization strategy is driving Chinese lithium battery companies to international capital markets, as local production is increasingly required due to geopolitical factors [11][12]. - The construction of localized production facilities in Europe, Southeast Asia, and North America is becoming essential for Chinese companies to integrate into global supply chains and meet local production requirements [11][12]. - The opportunity presented by the slow development of local battery companies in Europe and the U.S. creates a market window for Chinese firms to establish a presence and benefit from substantial local funding [12]. Group 4: Capital Market Changes - The tightening of IPO approvals in the A-share market has led many companies to seek more certain alternatives, such as the Hong Kong market, which offers a more accommodating environment for new listings [14]. - The Hong Kong capital market has shown greater inclusivity and efficiency, with recent regulatory changes aimed at expediting the IPO process for technology companies [14]. - Differences in valuation logic between A-share and Hong Kong markets influence companies' decisions, with Hong Kong investors placing a higher value on global competitiveness and long-term technological barriers [16][17]. Group 5: Strategic Implications - The choice to list in Hong Kong is not merely a response to overcapacity and financing pressures but also a strategic move to align with global capital narratives and enhance brand reputation [18]. - By entering the international capital market, companies can improve governance transparency and brand image, which are crucial for long-term global competitiveness [18].

Core Points - Multiple customers in Wuhan have reported issues with Ferrari vehicle deliveries and refunds from Wuhan Jun Dong Automobile Sales Company, with contracts signed in 2022 and 2023, and refunds promised in 2024 yet to be received [1] - The parent company, Yuntian (China) Investment Co., Ltd., is facing financial difficulties, leading to a lack of funds for refunds, and has suggested customers seek alternative solutions such as selling other vehicles or issuing lawyer letters [1][2] - Yuntian (China) Investment Co., Ltd. is a subsidiary of the Hong Kong Chow Tai Fook Group and has been an authorized dealer for Ferrari and Maserati in China since 2005, operating 23 sales companies across various cities [2] Company Issues - The Wuhan Jun Dong Automobile Sales Company has been reported to have a strained cash flow, with at least five customers awaiting refunds [1] - Several companies under the "Jun" brand have faced legal actions, including forced executions and tax penalties, indicating broader financial and operational challenges within the group [2] - Social media has seen numerous complaints from customers regarding undelivered vehicles and unfulfilled refund requests from "Jun" brand stores over the past two years [3]